United States Biopharmaceuticals Market 2025 | Growth Drivers, Trends & Market Forecast, Competitive Landscape & Investment Opportunities

Market Size and Growth

Biopharmaceuticals Market is estimated to reach at a CAGR of 7.80% over the forecast period 2024-2031.

Key Development:

United States: Recent Biopharmaceutical Developments

✅ In September 2025, UniQure's experimental gene therapy, AMT-130, demonstrated a 75% slowdown in Huntington's disease progression over three years. The company plans to apply for FDA approval in early 2026.

✅ In July 2025, AstraZeneca announced a $50 billion investment in the U.S. by 2030, including a new manufacturing facility in Virginia focused on chronic disease treatments.

✅ In September 2025, GSK committed $30 billion to U.S. research and development over the next five years, including a new factory in Pennsylvania for cancer drugs.

Japan: Recent Biopharmaceutical Developments

✅ In September 2025, Alvotech and Fuji Pharma received marketing approval in Japan for three new biosimilars, expanding access to biologic treatments.

✅ In August 2025, Japan's AMED announced a 2:1 matching grant program for biopharma startups, offering up to $44.5 million in non-dilutive funding to support drug development.

✅ In July 2025, Japanese companies, including Nikon and AGC, announced a $675 million investment by 2027 to enhance production of advanced drugs like stem cell-based and gene therapies.

Get a Free Sample PDF Of This Report (Get Higher Priority for Corporate Email ID):- https://www.datamintelligence.com/download-sample/biopharmaceuticals-market?sb

Biopharmaceuticals are therapeutic products produced using biological sources, such as proteins, nucleic acids, or living cells. They include vaccines, monoclonal antibodies, and gene therapies, offering targeted treatment for diseases, personalized medicine solutions, and advances in healthcare innovation.

Recent Mergers and Acquisitions:

United States: Recent Biopharmaceutical M&A

✅ In September 2025, Roche announced the acquisition of U.S.-based 89bio for up to $3.5 billion. The deal includes an upfront payment of $14.50 per share and potential milestone payments of up to $6 per share. 89bio is developing pegozafermin, a drug targeting metabolic dysfunction-associated steatohepatitis (MASH), with phase-3 trial results expected in 2027-2028.

✅ In September 2025, Pfizer acquired weight-loss drug developer Metsera for up to $7.3 billion. The deal involves an upfront cash payment of $47.50 per share, with additional contingent payments based on clinical and regulatory milestones. Metsera's lead candidate, MET-097i, showed an 11.3% body mass reduction in phase-two trials with limited side effects.

✅ In May 2025, Johnson & Johnson completed its $14.6 billion acquisition of Intra-Cellular Therapies, a company developing therapeutics for central nervous system disorders. This acquisition is one of the largest in the biopharma sector in 2025.

Other :

✅ In April 2025, Novartis announced plans to acquire Regulus Therapeutics for up to $1.7 billion. The acquisition includes an upfront cash payment of $7 per share, totaling approximately $800 million, with additional contingent payments based on regulatory milestones. Regulus is developing RGLS8429, an oligonucleotide targeting microRNA-17, for the treatment of autosomal dominant polycystic kidney disease (ADPKD). The transaction is expected to close in the second half of 2025.

✅ In April 2025, Germany's Merck KGaA announced a definitive agreement to acquire U.S.-based SpringWorks Therapeutics in an all-cash deal valued at $3.9 billion. The acquisition aims to bolster Merck's rare cancer therapies portfolio, particularly following recent setbacks in late-stage trials. SpringWorks is anticipating a positive opinion from the European CHMP for its desmoid tumor treatment, Ogsiveo (nirogacestat).

Key Players:

=> Abbvie Inc., Amgen Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Johnson & Johnson, Novartis AG, Novo Nordisk AS, Pfizer Inc., GlaxoSmithKline PLC, and F. Hoffmann-La Roche AG among others.

Growth Forecast Projected:

The Global Biopharmaceuticals Market is anticipated to rise at a considerable rate during the forecast period, between 2024 and 2031. In 2023, the market is growing at a steady rate, and with the rising adoption of strategies by key players, the market is expected to rise over the projected horizon.

Research Process:

Both primary and secondary data sources have been used in the global Biopharmaceuticals Market research report. During the research process, a wide range of industry-affecting factors are examined, including governmental regulations, market conditions, competitive levels, historical data, market situation, technological advancements, upcoming developments, in related businesses, as well as market volatility, prospects, potential barriers, and challenges.

Buy Now & Unlock 360° Market Intelligence: https://www.datamintelligence.com/buy-now-page?report=biopharmaceuticals-market

Key Segments:

➥ By Type: Monoclonal Antibody, Recombinant Growth Factors, Purified Proteins, Recombinant Proteins, Recombinant Hormones, Synthetic Immunomodulators, Vaccines, Recombinant Enzymes
➥ By Application: Oncology, Autoimmune Disorders, Metabolic Disorders, Hormonal Disorders, Disease Prevention, Cardiovascular Diseases, Neurological Diseases

Regional Analysis for Biopharmaceuticals Market:

⇥ North America (U.S., Canada, Mexico)

⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

⇥ South America (Colombia, Brazil, Argentina, Rest of South America)

⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Benefits of the Report:

Chapter 1: Sets the stage by outlining the report's coverage, summarizing key market segments by region, product type, and application. Presents a snapshot of market sizes, growth potential across segments, and anticipated industry evolution both short and long term.

Chapter 2: Highlights pivotal market insights and uncovers the most significant emerging trends driving change within the industry.

Chapter 3: Offers an in-depth look at the competitive landscape among Biopharmaceuticals producers, including revenue shares, strategic moves, and recent mergers and acquisitions.

Chapter 4: Presents comprehensive profiles of the market's key players, delving into details such as revenue, profit margins, product portfolios, and company milestones.

Chapters 5 & 6: Analyze Biopharmaceuticals revenue at both regional and country levels, providing quantitative breakdowns of market sizes, growth opportunities, and development prospects worldwide.

Chapter 7: Focuses on different market segments by type, examining their individual sizes and potential, guiding readers toward high-impact, untapped market areas.

Chapter 8: Explores segmentation by application, evaluating industry growth potential in various downstream markets and pinpointing promising sectors for expansion.

Chapter 9: Provides a thorough review of the industry's supply chain mapping out both upstream and downstream activities.

Chapter 10: Concludes with a summary of the report's key findings and highlights the most critical takeaways for industry stakeholders.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/biopharmaceuticals-market?sb

FAQ

Q: What is the growth rate of the Biopharmaceuticals Market?

A: The market is projected to expand at a compound annual growth rate (CAGR) of 7.80% during the forecast period from 2024 to 2031.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription?sb

Power your decisions with real-time competitor tracking, strategic forecasts, and global investment insights all in one place.

✅ Competitive Landscape
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Unmet Needs & Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Quarterly Industry Report Updated
✅ Live Market & Pricing Trends
✅ Import-Export Data Monitoring

Have a look at our Subscription Dashboard: https://www.youtube.com/watch?v=x5oEiqEqTWg?sb

Contact Us -

Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -

DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.

Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.